Looking Ahead: The Evolving Oncology Landscape
Summary
Avalere experts examined the changing oncology landscape amid the COVID-19 pandemic.
Please note: This is an archived post. Some of the information and data discussed in this article may be out of date. It is preserved here for historical reference but should not be used as the basis for business decisions. Please see our main Insights section for more recent posts.
The oncology landscape continues to evolve, with delays to preventative screenings and care during the COVID-19 pandemic and an influx of approved immunotherapy and other targeted therapy products. Stakeholders will be impacted by a changing payer mix with growth in managed markets, continued investment in diagnosis and treatment options, and a focus on value. Join us for a discussion on these shifts and what to expect going forward.
Key Topics:
- Impact of COVID-19 on access and health equity, including insurance coverage shifts, changes in reimbursement, and telehealth adoption
- Areas of innovation and market growth, including advances in diagnosis and treatment
- Strategies to demonstrate value, especially for targeted therapies
Panelists
Related Content
